Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00712556 · ClinicalTrials.gov registry record
PET Study in Patients With Non-Hodgkin Lymphoma
A clinical trial, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- 55
- Enrollment target
NCT00712556 is a clinical trial that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 55 participants.
The verdict
NCT00712556 has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- 55 participants
- Enrollment target
Study Summary
RATIONALE: Diagnostic procedures, such as fluorine 18-fludeoxyglucose positron emission tomography (PET) scans, may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase I trial is studying fluorine 18-fludeoxyglucose PET scan to see how well it predicts outcomes in patients who have undergone high-dose chemotherapy and autologous stem cell transplant for non-Hodgkin lymphoma.
Interventions
- RADIATION fluorine 18-fludeoxyglucose positron emission tomography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00712556
The ClinicalTrials.gov registry entry for NCT00712556 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which fluorine 18-fludeoxyglucose positron emission tomography is the first listed.
NCT00712556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00712556 about?
NCT00712556 is a clinical study titled "PET Study in Patients With Non-Hodgkin Lymphoma". RATIONALE: Diagnostic procedures, such as fluorine 18-fludeoxyglucose positron emission tomography (PET) scans, may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase I trial is studying fluorine 18-fludeoxyglucose PET scan to see how well i...
What is the current status of trial NCT00712556?
This trial is currently completed. The enrollment target is 55 participants. The study started on 2008-05. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00712556?
The interventions under investigation include: fluorine 18-fludeoxyglucose positron emission tomography (RADIATION).
Who is sponsoring clinical trial NCT00712556?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.